Phase Ib, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Any Solid Cancer and Sequential Phase II, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Second Line Treatment

NCT02447406 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

7

Enrollment

OTHER

Sponsor class

Conditions

Advanced Gastric Adenocarcinoma

Interventions

DRUG: AZD6094
DRUG: docetaxel

Sponsor

Samsung Medical Center